Build status - In Progress

A Open-Label Ascending Dose Study to Evaluate the Safety and Effects of PR001A in Patients With Parkinson's Disease

A Open-Label Ascending Dose Study to Evaluate the Safety and Effects of PR001A in Patients With Parkinson's Disease
Recruiting
35 years - 80 years
All
Phase 1
12 participants needed
1 Location

Brief description of study

This is a 5 year study and the purpose is to assess the safety and tolerability of 2 dose levels of PR001A administered via l injection in patients with moderate to severe Parkinson's Disease

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Parkinson's Disease
  • Age: 35 years - 80 years
  • Gender: All

Male or Female Age 35-80 (BMI) of 18 to 34 Diagnosis of Parkinson's Disease

Updated on 04 Aug 2024. Study ID: 843759

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center